Analyst Benjamin Burnett of Stifel Nicolaus maintained a Buy rating on Jasper Therapeutics (JSPR – Research Report), retaining the price target of $80.00.
Benjamin Burnett has given his Buy rating due to a combination of factors surrounding Jasper Therapeutics. The company has shown promising initial data for its drug briquilimab, which appears to perform comparably to a competitor’s product, barzolvolimab, with potential for even greater efficacy if higher dose trends continue. The management has outlined a clear strategy to provide more data mid-year, which could further clarify briquilimab’s safety and efficacy profile, particularly at higher doses.
Despite the stock being priced with high skepticism, nearly at cash value, Burnett sees potential upside if the drug can differentiate itself in the market. The management’s confidence in having identified the optimal dosing range, coupled with the potential for strategic interest from asthma data expected in the second half of 2025, adds to the positive outlook. The analyst believes that even if the drug is slightly behind in development timelines, its comparable clinical profile to existing treatments could still hold significant value.
In another report released yesterday, BTIG also maintained a Buy rating on the stock with a $64.00 price target.